Clinical Trials on Preleukemia

Total 1578 results

Kirsten Grønbæk
Zealand University Hospital; University of Copenhagen; Herlev Hospital; Steno Diabetes... and other collaborators

Recruiting

Repurposing Metformin as a Leukemia-preventive Drug in CCUS and LR-MDS

Preleukemia | Cytopenia | Myelodysplastic Neoplasm | Preleukemic Anemia

Denmark
Peter MacCallum Cancer Centre, Australia
Celgene Corporation

Unknown

Lenalidomide and Recombinant Human Stem Cell Factor for Treatment of Myelodysplasia

Myelodysplasia

Australia
University Hospital, Grenoble
Novartis

Recruiting

Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA Agents (LODEFI)

Myelodysplasia

France
Massachusetts General Hospital
Dana-Farber Cancer Institute; Celgene Corporation

Completed

A Phase 1 Dose Escalating Trial of Bortezomib in Combination With Lenalidomide in Patients With Myelodysplasia

Myelodysplasia

United States
Fondazione Italiana Sindromi Mielodisplastiche-ETS
Istituto Clinico Humanitas

Completed

Efficacy and Safety of Luspatercept: A Study by Fondazione Italiana Sindromi Mielodisplastiche (FISiM-Luspa)

Myeloid Dysplasia

Italy
Celgene

Completed

Post Marketing Surveillance to Collect and Evaluate the Safety and Efficacy Information of Korean MDS Patients Treated With VIDAZA®, After Approval of Marketing Authorization for New Drug in Korea

Myelodysplastic Syndrome

Korea, Republic of
University of Chicago

Completed

Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies

Leukemia | Preleukemia | Advanced Hematologic Malignancies

United States
Saint-Louis Hospital, Paris, France
University Hospital, Clermont-Ferrand; University Hospital, Grenoble; Hospital...

Completed

Allogeneic Hematopoietic Stem Cell Transplantation Evaluation in High Risk Myelodysplasia: an Observational Non-interventional Study (ONIalloMDS)

Myelodysplasia

France
Technische Universität Dresden

Not yet recruiting

Lifestyle-modifying Interventions in Low-risk MDS Patients (MDS-LIME)

Myelodysplastic Syndromes
Groupe Francophone des Myelodysplasies

Recruiting

A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS (EPO-PRETAR)

Myelodysplastic Syndromes

France
Sidney Kimmel Comprehensive Cancer Center at Johns...

Terminated

Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage Dysplasia

Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center
Teva Pharmaceuticals USA

Completed

Omacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure

Leukemia

United States
H. Lee Moffitt Cancer Center and Research Institute
Celgene

Completed

Immunotherapy Using Lenalidomide + Bystander Vaccine in High Risk Myelodysplastic Syndrome (MDS)

Leukemia

United States
M.D. Anderson Cancer Center
Millennium Pharmaceuticals, Inc.

Completed

Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation

Leukemia

United States
Sunnybrook Health Sciences Centre
Health Sciences Centre, Winnipeg, Manitoba; The Ottawa Hospital; Jewish General... and other collaborators

Unknown

MDS-CAN: A Prospective National MDS Clinical Database and Local Tissue Bank (MDS)

Myelodysplastic Syndrome (MDS)

Canada
M.D. Anderson Cancer Center

Terminated

Study of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS)

Leukemia

United States
M.D. Anderson Cancer Center
Celgene Corporation

Terminated

Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)

Leukemia

United States
Massachusetts General Hospital
Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Brigham and...

Terminated

Study of Velcade and Thalidomide in Patients With Myelodysplasia

Myelodysplastic Syndrome

United States
Massachusetts General Hospital
Novartis

Recruiting

MBG453 in Lower Risk MDS

Myelodysplastic Syndromes

United States
Technische Universität Dresden

Recruiting

Study Investigating the Interactions of Bone and Hematopoiesis in the Elderly

Myelodysplastic Syndromes

Germany
Xiao Li

Unknown

Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS

Myelodysplastic Syndromes

China
Longbio Pharma

Active, not recruiting

A Study of Single and Multiple Dose Administration of LP-001 in Healthy Subjects

Myelodysplastic Syndrome (MDS)

China
Otsuka Australia Pharmaceutical Pty Ltd

Completed

Refine and Assess the Readability of Patient, Carer, and Clinician Treatment Preference in Myelodysplasia Questionnaire (TPMQ)

Myelodysplastic Syndrome (MDS)

Australia
Yale University

Withdrawn

CPX-351 in Patients Treated for Higher-risk Myelodysplastic Syndromes Experiencing Hypomethylating Agent Failure.

MDS

United States
M.D. Anderson Cancer Center

Completed

Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk

Leukemia

United States
M.D. Anderson Cancer Center
GlaxoSmithKline; Novartis

Completed

Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)

Leukemia

United States
Celgene

Completed

A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q (MDS-005)

Anemia

United States, Belgium, Spain, United Kingdom, Austria, Canada, Germany, Portugal, France, Australia, Israel, Japan, Italy, Czechia, Poland, Turkey
Assistance Publique - Hôpitaux de Paris

Unknown

Best Promising Drug Association With Azacitidine in Higher Risk Myelodysplastic Syndromes (AZA-PLUS)

MDS

France
Groupe Francophone des Myelodysplasies
Novartis

Completed

A Study of LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients (LDE255)

MDS

France
Gruppo Italiano Malattie EMatologiche dell'Adulto

Terminated

Velcade in Myelodysplastic Syndrome - Pilot Study

MDS

Italy
Kyowa Kirin Co., Ltd.

Completed

A Clinical Study of KRN321 in Adult Subjects With Myelodysplastic Syndrome

MDS

Japan, Korea, Republic of
Sherif Farag

Withdrawn

Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia

Aml | AML, Adult
Dongzhimen Hospital, Beijing

Not yet recruiting

Clinical Efficacy and Mechanism of Yisui Granule in Treatment of Low and Medium Risk Myelodysplastic Syndrome Through Demethylation

MDS
Groupe Francophone des Myelodysplasies
Novartis; Neovii Biotech

Active, not recruiting

Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk

MDS

France
Aprea Therapeutics

Completed

APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)

MDS

United States, France
M.D. Anderson Cancer Center
Incyte Corporation

Completed

Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Leukemia

United States
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

Study of ACE-536 for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)

Anemia

Germany
Rush University Medical Center
Celgene Corporation

Terminated

A Trial of Lenalidomide & Azacitidine in Low Risk Myelodysplastic Syndromes

MDS

United States
M.D. Anderson Cancer Center
Bristol-Myers Squibb

Terminated

Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)

Leukemia

United States
M.D. Anderson Cancer Center
CTI BioPharma

Terminated

Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)

Leukemia

United States
Amgen

Completed

Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

MDS

Germany, Italy, Belgium, Czechia, Switzerland, France, Austria, Greece, Spain
M.D. Anderson Cancer Center
S*BIO

Terminated

SB1518 for Patients With Myelodysplastic Syndrome (MDS)

Leukemia

United States
H. Lee Moffitt Cancer Center and Research Institute
Celgene Corporation

Completed

Pre-Transplant 5-Azacitidine In Patients With High-Risk Myelodysplastic Syndrome Who Are Candidates For Allogeneic Hematopoietic Cell Transplant

Leukemia

United States
Otsuka Pharmaceutical Co., Ltd.

Active, not recruiting

Phase 1 Trial of ASTX727 in Subjects With Lower-risk Myelodysplastic Syndromes

Lower-risk Myelodysplastic

Japan
Novartis Pharmaceuticals

Terminated

Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox.

High Risk MDS

United States
Wuhan Union Hospital, China

Not yet recruiting

A Novel Conditioning Regimen for Myelodysplastic Syndrome With Moderate High IPSS-M Score

Myelodysplastic Syndromes
Otsuka Beijing Research Institute

Recruiting

PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes

Myelodysplastic Syndromes

China
Bristol-Myers Squibb

Recruiting

A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants (MAXILUS)

Myelodysplastic Syndromes

Spain, United States, France, Italy, Belgium, Germany, Poland, Czechia, Puerto Rico
Peking Union Medical College Hospital

Not yet recruiting

Roxadustat Combined With Luspatercept Versus Luspatercept Monotherapy in the Treatment of Refractory MDS-RS

Myelodysplastic Syndromes

China
Bristol-Myers Squibb

Recruiting

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes

United States, Japan, Argentina, Hong Kong, Greece, Italy, China, Australia, Spain, Austria, Denmark, Germany, Sweden, Switzerland, Canada, Czechia, Korea, Republic of, Poland, Turkey, France

3

Subscribe